書誌情報
IS5-6. A phase2 trial assessing osimertinib activity against leptomeningeal carcinomatosis EGFR-mutant
Shigeki Nanjo1,5,7, Yuki Akazawa2, Motohiro Tamiya3, Akito Hata4,5, Toshihiko Yamaguchi2, Sachiko Arai7, Toru Kumagai3, Masahide Mori2, Seiji Yano7, Nobuyuki Katakami5,6
1Division of Hematology / Oncology, University of Califonia, 2National Hospital Organization Toneyama National Hospital, 3Osaka International Cancer Institute, 4Kobe Minimally Invasive Cancer Center, 5Kobe City Medical Center General Hospital, 6Takarazuka City Hospital, 7Kanazawa University Cancer Research Institute
Japanese Journal of Lung Cancer 59(6): 631-631, 2019.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
